Cited by 2,393Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, Stefan S., Kempf-Bielack, Beate, Delling, Günter, Exner, G. Ulrich, Flege, Silke, Helmke, Knut, Kotz, Rainer, Salzer-Kuntschik, Mechthild, Werner, Matthias, Winkelmann, Winfried, Zoubek, Andreas, Jürgens, Heribert, Winkler, Kurt·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.776

Open this paper in CoChat — free account

Abstract

PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-year survival ≥ 40, 41.6%; < 40, 60.2%; P = .012), tumor site (axial, 29.2%; limb, 61.7%; P < .0001), and primary metastases (yes, 26.7%; no, 64.4%; P < .0001), and for extremity osteosarcomas, also size (≥ one third, 52.5%; < one third, 66.7%; P < .0001) and location within the limb (proximal, 49.3%; other, 63.9%; P < .0001), had significant influence on outcome. Two additional important prognostic factors were treatment related: response to chemotherapy (poor, 47.2%; good, 73.4%; P < .0001) and the extent of surgery (incomplete, 14.6%; macroscopically complete, 64.8%; P < .0001). All factors except age maintained their significance in multivariate testing, with surgical remission and histologic response emerging as the key prognostic factors. CONCLUSION: Tumor site and size, primary metastases, response to chemotherapy, and surgical remission are of independent prognostic value in osteosarcoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.776

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
The Analysis of Binary Data.
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2344247 · Cited by 2,274
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,171
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B. M., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6 · Cited by 1,082
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675

Flagged first, then by citations

Show all 61 references

Sorted by citations

Items 501–600 of 1,001

Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don't eat me’ signals off and ‘eat me’ signals on
Mohanty, S., Aghighi, M., Yerneni, K., Theruvath, J. L., & Daldrup-Link, H. E. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12556 · Cited by 46
Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA‐424 in osteosarcoma
Hu, Y., Gu, J., Shen, H., Shao, T., Li, S., Wang, W., & Yu, Z. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23045 · Cited by 44
PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma
Chen, C., Guo, Y., Huang, Q., Wang, B., Wang, W., Niu, J., Lou, J., Xu, J., Ren, T., Huang, Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215660 · Cited by 45
Osteosarcoma of the Hand and Forearm: Experience of the Cooperative Osteosarcoma Study Group
Daecke, W., Bielack, S., Martini, A.-K., Ewerbeck, V., Jürgens, H., Kotz, R. I., Winkelmann, W., Kabisch, H., Kevric, M., & Bernd, L. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.06.002 · Cited by 45
Self-citation
Osteosarcoma of the Femur with Skip, Lymph Node, and Lung Metastases
Zwaga, T., Bovée, J. V. M. G., & Kroon, H. M. J. A. (2008) · Radiographics · doi:10.1148/rg.281075015 · Cited by 45
“The proximal part of the tibia and humerus are also commonly involved, followed by the proximal part of the femur and pelvis (4,5).”
Background
Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells
Kubo, T., Shimose, S., Matsuo, T., Tanaka, K., Yasunaga, Y., Sakai, A., & Ochi, M. (2006) · Journal of Orthopaedic Research® · doi:10.1002/jor.20177 · Cited by 46
“The purpose of our study was to investigate the antitumor effects of MIN on common primary malignant bone tumors, including OS, CS, and ES.”
Background
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells
van Valen, F., Fulda, S., Schäfer, K.-L., Truckenbrod, B., Hotfilder, M., Poremba, C., Debatin, K., & Winkelmann, W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11503 · Cited by 45
Self-citation
Dear John Hunter
Messiou, C., Vanel, D., Pollock, R. C., Cooke, M., Moskovic, E. C., Savidge, C., King, L., Patel, A. B., & Jones, R. L. (2016) · BMJ · doi:10.1136/bmj.i6515 · Cited by 44
18F-FDG PET/CT in the Management of Osteosarcoma
Oh, C., Bishop, M. W., Cho, S. Y., Im, H., & Shulkin, B. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265592 · Cited by 45
“Prognostic Factors Tumor site, size, primary metastases, response to chemotherapy, and surgical remission are the reported independent prognostic factors in osteosarcoma (3).”
BackgroundInfluential
Extracellular-vesicle-packaged S100A11 from osteosarcoma cells mediates lung premetastatic niche formation by recruiting gMDSCs
Deng, C., Xu, Y., Chen, H., Zhu, X., Huang, L., Chen, Z., Xu, H., Song, G., Lu, J., Huang, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113751 · Cited by 45
Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins
Lv, T.-Z., & Wang, G. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2480 · Cited by 44
“Respiratory failure due to lung metastasis is the major cause of mortality in patients, despite significant improvements in clinical treatments with combination intensive chemotherapy and surgical resection (4,5).”
High-intensity focused ultrasound: Noninvasive treatment for local unresectable recurrence of osteosarcoma
Yu, W., Tang, L., Lin, F., Yao, Y., Shen, Z., & Zhou, X. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2014.10.001 · Cited by 44
“3% of all osteosarcomas [24], complete resection is sometimes difficult because of the location and extension of the tumor.”
Background
The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma
Xiao, X., Wang, W., & Wang, Z. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0095-z · Cited by 44
“6:1; females have a peak incidence a little earlier than males due to the earlier onset of their growth spurt [2–7].”
Background
Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
Rettew, A. N., Young, E. D., Lev, D. C., Kleinerman, E. S., Abdul‐Karim, F. W., Getty, P. J., & Greenfield, E. M. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.34 · Cited by 43
MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93
Montanini, L., Lasagna, L., Barili, V., Jonstrup, S. P., Murgia, A., Pazzaglia, L., Conti, A., Novello, C., Kjems, J., Perris, R., et al. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0059-z · Cited by 44
“In recent years surgery combined with chemotherapy has markedly improved patient survival [2]; however the use of anti-cancer drugs is still associated with serious problems, such as frequent acquisitions of drug-resistant phenotypes, highlighting the need for urgent novel treatment approaches [3].”
Background
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
Graat, H. C. A., Witlox, A. M. A., Schagen, F. H. E., Kaspers, G. J. L., Helder, M. N., Bras, J., Schaap, G. R., Gerritsen, W. R., Wuisman, P. I. J. M., & van Beusechem, V. W. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603189 · Cited by 44
“Improvement of chemotherapeutic drug regimens and surgical techniques resulted in an overall event-free survival rate of approximately 50–70% (Link et al, 1986; Bacci et al, 2001; Bielack et al, 2002).”
Background
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors
Degnan, A. J., Chung, C. Y., & Shah, A. J. (2017) · Clinical Imaging · doi:10.1016/j.clinimag.2017.08.003 · Cited by 44
Theabrownin triggers DNA damage to suppress human osteosarcoma U2 OS cells by activating p53 signalling pathway
Jin, W., Zhou, L., Yan, B., Li, Y., Liu, F., Tong, P., Yu, W., Dong, X., Xie, L., Zhang, J., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13742 · Cited by 44
“Approximately 15% to 20% of patients have clinically detectable metastases with more than 85% of occurrence in the lungs.(2,5) The world-wide annual incidence of OS is 3.”
Background
Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study
Song, K., Song, J., Lin, K., Chen, F., Ma, X., Jiang, J., & Li, F. (2019) · International Orthopaedics · doi:10.1007/s00264-019-04348-4 · Cited by 42
miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b
Liu, Q., Wang, Z., Zhou, X., Tang, M., Tan, W., Sun, T., & Deng, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1676087 · Cited by 44
“Patients with OS who have undergone modern treatment approaches, including chemotherapy and surgery, only maintain a 5-year survival rate of 60 to 70 percent [1,2].”
Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF‐α and melphalan
Grabellus, F., Kraft, C., Sheu‐Grabellus, S., Bauer, S., Podleska, L. E., Lauenstein, T. C., Pöttgen, C., Konik, M., Schmid, K. W., & Taeger, G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21724 · Cited by 44
“In the present study, we applied a modified Salzer-Kuntschik grading system [20] that is used in highly malignant bone tumors and which serves as an independent prognostic factor [22].”
Method
Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture
YIN, K., Liao, Q., Zhong, D., Ding, J., NIU, B., LONG, Q., & Ding, D. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.685 · Cited by 44
“…choice of limb salvage or amputation can have an impact on patient outcome in these cases, including tumor size (24), poor response to chemotherapy (25), serum lactate dehydrogenase levels (26,27), anatomical location (9), unstable fracture without healing, age (28), histologic subtype (26), and…”
A Nomogram for Predicting Cancer-Specific Survival of Osteosarcoma and Ewing's Sarcoma in Children: A SEER Database Analysis
Wang, J., Zhanghuang, C., Tan, X., Mi, T., Liu, J., Jin, L., Li, M., Zhang, Z., & He, D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.837506 · Cited by 44
“Like previous studies, axial tumor location predicts the worst prognosis (36, 37).”
Result
Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways
Wu, C., Tan, J., Shen, H., Deng, C., Kleber, C., Osterhoff, G., & Schopow, N. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00999-7 · Cited by 49
“Despite advances in treatment, the prognosis for patients with osteosarcoma remains poor, with a 5-year survival rate of approximately 60–70% for localized disease and less than 30% for metastatic disease [1].”
Background
Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment
Xiao, G., Wang, X., Xu, Z., Liu, Y., & Jing, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02318-6 · Cited by 44
Changes in Health Status Among Aging Survivors of Pediatric Upper and Lower Extremity Sarcoma: A Report From the Childhood Cancer Survivor Study
Marina, N. M., Hudson, M. M., Jones, K., Mulrooney, D. A., Avedian, R. S., Donaldson, S. S., Popat, R. A., West, D. W., Fisher, P. G., Leisenring, W. M., et al. (2013) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2013.01.013 · Cited by 43
Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma
Hagleitner, M. M., de Bont, E. S. J. M., & Loo, D. M. W. M. T. (2012) · Sarcoma · doi:10.1155/2012/636405 · Cited by 43
“These findings are in concordance with earlier reports in the literature [12, 13].”
Result
Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy
Liu, S., Zhi, Y., Ling, M., Shi, J., Qiu, Y., & Yang, S. (2014) · Tumor Biology · doi:10.1007/s13277-014-1917-x · Cited by 43
“However, more than 40 % patients show a poor response to chemotherapy, with an estimated survival of 45 to 55 % [6].”
Background
Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells
Benassi, M. S., Chiechi, A., Ponticelli, F., Pazzaglia, L., Gamberi, G., Zanella, L., Manara, M. C., Perego, P., Ferrari, S. M., & Picci, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.004 · Cited by 43
CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells
Tsai, H., Huang, C., Su, H., & Tang, C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.007 · Cited by 44
Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors
Issaq, S. H., Teicher, B. A., & Monks, A. P. (2014) · Cell Cycle · doi:10.4161/cc.28010 · Cited by 43
“Despite treatment protocols that combine chemotherapy, surgery, and sometimes radiotherapy, the 5-year survival rate for patients diagnosed with osteosarcoma is 60–70%.(6,8) The long-term survival rate for patients with metastatic disease detectable at presentation is 30–35%.”
Background
Global Gene Expression Profiling of Human Osteosarcomas Reveals Metastasis-Associated Chemokine Pattern
Namløs, H. M., Kresse, S. H., Müller, C. R., Henriksen, J. M., Holdhus, R., Sæter, G., Bruland, Ø. S., Bjerkehagen, B., Steen, V. M., & Myklebost, O. (2012) · Sarcoma · doi:10.1155/2012/639038 · Cited by 42
“Hindawi Publishing Corporation Sarcoma Volume 2012, Article ID 639038, 12 pages doi:10.1155/2012/639038”
BackgroundInfluential
Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells
Iwasaki, T., Tanaka, K., Kawano, M., Itonaga, I., & Tsumura, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2867 · Cited by 42
One-year mortality in patients with bone and soft tissue sarcomas as an indicator of delay in presentation
Nandra, R. S., Hwang, N., Matharu, G., Reddy, K., & Grimer, R. J. (2015) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588415x14181254790284 · Cited by 43
“The factors identified have been established previously in the literature when considering mid to long-term survival.(11,12,15,22) Our results are therefore not novel but reinforce what has been described in three, five and ten-year survival studies, validating our findings.”
BackgroundResult
Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis
Kubo, T., Furuta, T., Johan, M. P., Adachi, N., & Ochi, M. (2016) · Skeletal Radiology · doi:10.1007/s00256-016-2410-y · Cited by 43
Telangiectatic osteosarcoma: a review of 87 cases
Angelini, A., Mavrogenis, A. F., Trovarelli, G., Ferrari, S., Picci, P., & Ruggieri, P. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2210-8 · Cited by 44
“Some studies on OS have demonstrated different results about tumor site and survival (Durnali et al. 2013; Bacci et al. 2006; Bispo Júnior and Camargo 2009; Bielack et al. 2002; Xie et al. 2012; Goorin et al. 1987; Pakos et al. 2009; Bramer et al. 2009), but few studies have investigated the TOS site as a prognostic v…”
BackgroundMethodResultInfluential
What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors?
Theil, C., Röder, J., Gosheger, G., Deventer, N., Dieckmann, R., Schorn, D., Hardes, J., & Andreou, D. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000955 · Cited by 43
“On the other hand, this is rather a reflection of the anatomical distribution of primary bone sarcomas [2, 26] and of the health status of the mostly young patients, so that we believe that our main findings will be useful for patient consultation in everyday practice.”
Background
Naringenin Induces ROS-Mediated ER Stress, Autophagy, and Apoptosis in Human Osteosarcoma Cell Lines
Lee, C., Huang, C. C., Chi, M., Lee, K., Peng, K., Fang, M.-L., Chiang, Y., & Liu, J. (2022) · Molecules · doi:10.3390/molecules27020373 · Cited by 44
“The 5-year survival rate of patients with localized osteosarcoma is 65–75% [5]; however, the prognosis of patients with relapse and metastasis is poor, with a 5-year survival rate of 10–20% [6,7].”
Background
Improved Survival in Primary Nonmetastatic Pediatric Osteosarcoma of the Extremity
Wilkins, R. M., Cullen, J. W., Camozzi, A. B., Jamroz, B. A., & Odom, L. F. (2005) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000179736.10871.76 · Cited by 42
“The percent tumor necrosis induced by neoadjuvant therapy has been found to be the most important prognostic factor in the treatment of nonmetastatic osteosarcoma of the extremity.(7,12,22) We hypothesized that the percent tumor necrosis could be maximized by using the two most active agents repetitively.”
Background
Emerging 2D Nanomaterials‐Integrated Hydrogels: Advancements in Designing Theragenerative Materials for Bone Regeneration and Disease Therapy
Zorrón, M., Cabrera, A. L., Sharma, R., Radhakrishnan, J., Abbaszadeh, S., Shahbazi, M., Tafreshi, O. A., Karamikamkar, S., & Maleki, H. H. (2024) · Advanced Science · doi:10.1002/advs.202403204 · Cited by 50
Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy
Robl, B., Pauli, C., Botter, S. M., Bode‐Lesniewska, B., & Fuchs, B. (2015) · BMC Cancer · doi:10.1186/s12885-015-1397-4 · Cited by 42
“Specifically for osteosarcoma, a patient’s response to neoadjuvant chemotherapy has a considerable prognostic value and has therefore replaced single adjuvant chemotherapy [5, 6].”
Background
Gender and ploidy in cancer survival
Schulze, S., & Petersen, I. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0013-0 · Cited by 42
Osteosarcoma in Asian Populations Over the Age of 40 Years: A Multicenter Study
Joo, M. W., Shin, S. H., Kang, Y.-K., Kawai, A., Kim, H. S., Asavamongkolkul, A., Jeon, D., Kim, J. D., Niu, X., Tsuchiya, H., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4414-6 · Cited by 42
The relation of tumour necrosis and survival in patients with osteosarcoma
Li, X., Ashana, A. O., Moretti, V. M., & Lackman, R. D. (2011) · International Orthopaedics · doi:10.1007/s00264-011-1209-7 · Cited by 43
“larger sample size, but the five-year OS of 65.9% in our study group was similar to the 65.3% [ 7 ], 66.2% [2] and 68.1% [6] reported in those studies.”
BackgroundResultInfluential
Imaging of Lymphoma of the Musculoskeletal System
Hwang, S. (2008) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2008.03.008 · Cited by 42
Autism Speaks: meeting on folate metabolism and Autism spectrum disorders, March 19-20, 2009, Washington, DC.
Bajpai, J., Kumar, R., Sreenivas, V., Sharma, M. C., Khan, S. A., Rastogi, S., Malhotra, A., Gamnagatti, S., Kumar, R., Safaya, R., et al. (2011) · PubMed · doi:10.1097/mph.0b013e31820ff78e · Cited by 42
Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels
Huang, J., Deng, G., Liu, T., Chen, W., & Zhou, Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.157 · Cited by 42
Targeting the FOXM 1‐regulated long noncoding RNA TUG 1 in osteosarcoma
Li, Y., Zhang, T., Zhang, Y., Zhao, X., & Wang, W. (2018) · Cancer Science · doi:10.1111/cas.13765 · Cited by 41
“The primary sites of osteosarcoma are the distal femur (43%), proximal tibia (23%) and humerus (10%), and more than 85% of metastatic lesions migrate to the lungs.(2) After the application of chemotherapy in the early 1980s, the long‐term survival rate with this disease improved from less than 20% to 65%.”
Background
LncRNA DLX6‐AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR‐641/HOXA9 signaling pathway
Zhang, N., Meng, X., Mei, L., Zhao, C., & Chen, W. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28426 · Cited by 42
“The typical presentation of OS includes the onset of pain and swelling in the affected bone; a hallmark of the pain is that it is sufficiently intense to wake the patient from sleep.(17) Chemotherapy is the most important assisted therapy in the treatment of OS.”
Background
Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981–2002
Eyre, R., Feltbower, R. G., Mubwandarikwa, E., Jenkinson, H. C., Parkes, S. E., Birch, J. M., Eden, T. O. B., James, P. W., McKinney, P. A., Pearce, M. S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604837 · Cited by 42
Initial tumor size predicts histologic response and survival in localized osteosarcoma patients
Kim, M. S., Lee, S., Cho, W. H., Song, W. S., Koh, J., Lee, J. A., Yoo, J. Y., & Jeon, D. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20986 · Cited by 42
“Several studies evaluating the prognostic relevance of tumor size have reached inconsistent conclusions [2,3,4].”
Background
Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study
Kobayashi, E., Iyer, A. K., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2012) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-012-2610-2 · Cited by 41
“Although the cure rate of patients with diseases such as localized osteosarcoma (OS) and ovarian cancers has improved due to the introduction of combinatorial chemotherapy [6, 34], a large proportion of patients still respond poorly to drug treatment and have a high risk of local tumor relapse and metastasis to distan…”
Pediatric sarcomas occurring in adults
Maki, R. G. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20969 · Cited by 41
Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing Frozen Autograft
Miwa, S., Takeuchi, A., Ikeda, H., Shirai, T., Yamamoto, N., Nishida, H., Hayashi, K., Tanzawa, Y., Kimura, H. J., Igarashi, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071362 · Cited by 42
“Histological response to chemotherapy is one of the most important prognostic factors for patients with osteosarcoma [19,20].”
Background
Relative tumor burden predicts metastasis‐free survival in pediatric osteosarcoma
Lee, J. A., Kim, M. S., Kim, D. H., Lim, J. S., Yoo, J. Y., Koh, J. S., Lee, S., Jeon, D., & Park, K. D. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21446 · Cited by 41
“At present, the most powerful prognostic factor for localized osteosarcoma is histologic response to preoperative chemotherapy [13,14].”
Background
Prognostic value of Twist and E-cadherin in patients with osteosarcoma
Yin, K., Liao, Q., He, H., & Zhong, D. (2012) · Medical Oncology · doi:10.1007/s12032-012-0317-6 · Cited by 41
Age as prognostic factor in patients with osteosarcoma
Hagleitner, M. M., Hoogerbrugge, P. M., van der Graaf, W. T. A., Flucke, U. E., Schreuder, H. W. B., & Loo, D. M. W. M. T. (2011) · Bone · doi:10.1016/j.bone.2011.08.014 · Cited by 41
Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma
Shimizu, T., Ishikawa, T., Iwai, S., Ueki, A., Sugihara, E., Onishi, N., Kuninaka, S., Miyamoto, T. K., Toyama, Y., Ijiri, H., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0347 · Cited by 41
“Osteosarcoma is characterized by aggressive local growth and systemic hematogenous dissemination, which together confer a generally poor prognosis (1, 2).”
Background
BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation
Lewis, V. O., Devarajan, E., Cardó‐Vila, M., Thomas, D. G., Kleinerman, E. S., Marchiò, S., Sidman, R. L., Pasqualini, R., & Arap, W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704173114 · Cited by 41
“The current standard of care for high-grade osteosarcoma is an aggressive combination of high-dose methotrexate with doxorubicin (Adriamycin) and cisplatin (MAP) in the neoadjuvant and adjuvant settings, complemented by surgery when possible (2).”
Background
Limb Salvage Versus Amputation in Conventional Appendicular Osteosarcoma: a Systematic Review
Jauregui, J. J., Nadarajah, V., Munn, J. S., Pivec, R., Kapadia, B. H., Lerman, D. M., & Maheshwari, A. V. (2018) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-018-0725-y · Cited by 42
Silencing of miR‑19a‑3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN
Zhang, B., Liu, Y., & Zhang, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9592 · Cited by 41
“In the treatment of OS, the combination of chemotherapy and surgery has improved the overall 5-year survival rate of patients with OS (16).”
The Roles of Circular RNAs in Osteosarcoma
Zhang, Y., Li, J., Wang, Y., Jing, J., & Li, J. (2019) · Medical Science Monitor · doi:10.12659/msm.915559 · Cited by 42
“Osteosarcoma is a malignant tumor that is most common in the metaphyses of limbs in both children and teenagers [1], and the distal femur, humerus, and proximal tibia are hot spots [2].”
Background
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
for the Children’s Oncology Group, Kopp, L. M., Womer, R. B., Schwartz, C. L., Ebb, D. H., Franco, V. I., Hall, D. C., Barkauskas, D. A., Krailo, M., Grier, H. E., et al. (2019) · Cardio-Oncology · doi:10.1186/s40959-019-0050-9 · Cited by 41
Survival analysis of osteosarcoma patients: A 15-year experience
Yasin, N. F., Rashid, M. L. A., & Singh, V. A. (2020) · Journal of orthopaedic surgery · doi:10.1177/2309499019896662 · Cited by 41
Local delivery of sunitinib and Ce6 via redox-responsive zwitterionic hydrogels effectively prevents osteosarcoma recurrence
Yu, Z., Xiao, Z., Shuai, X., & Tian, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00970a · Cited by 41
Expandable Endoprostheses in Malignant Bone Tumors in Children: Indications and Limitations
Baumgart, R., & Lenze, U. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-77960-5_6 · Cited by 41
Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies
Gomes, C. M. F., Paassen, H. V., Romeo, S. O., Welling, M. M., Feitsma, R. I. J., Abrunhosa, A., Botelho, M. F., Hogendoorn, P. C. W., Pauwels, E. K. J., & Cleton-Jansen, A. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.07.011 · Cited by 41
“Nearly 50% of OS cases are either resistant to chemotherapy or acquire resistance during treatment [8].”
Background
Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics
Kikuta, K., Tochigi, N., Saito, S., Shimoda, T., Morioka, H., Toyama, Y., Hosono, A., Suehara, Y., Beppu, Y., Kawai, A., et al. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200900172 · Cited by 41
Effect of 25‐hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines
Thompson, L., Wang, S., Tawfik, O. W., Templeton, K. J., Tancabelic, J., Pinson, D. M., Anderson, H. C., Keighley, J. D., & Garimella, R. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.21585 · Cited by 42
Functional and oncologic outcome of cemented endoprosthesis for malignant proximal femoral tumors
Houdek, M. T., Watts, C. D., Wyles, C. C., Rose, P. S., Taunton, M. J., & Sim, F. H. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24339 · Cited by 41
Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt/β-catenin signaling in human osteosarcoma cells
Zhang, R., Li, Y., Tian, D.-D., Liu, Y., Wu, N., Zou, X., Chen, Q., Zhou, L., Deng, Z., & He, B. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3701 · Cited by 41
Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Proliferation and Metastasis of Osteosarcoma Cells by Targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b
Sun, Z., Zhang, T., & Chen, B. (2019) · Medical Science Monitor · doi:10.12659/msm.912703 · Cited by 41
“Although metastasis only occurs to approximately 15% to 20% of osteosarcoma patients, 10% to 30% of long-term survival rates is extremely low compared with 65% and 70% in non-metastasis patients [29,30].”
Background
The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis
Xu, S., Gong, Y., Yin, Y., Xing, H., & Zhang, N. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110141 · Cited by 40
The Metastasectomy and Timing of Pulmonary Metastases on the Outcome of Osteosarcoma Patients
Huang, Y.-M., Hou, C., Hou, S., & Yang, R. (2009) · Clinical medicine Oncology · doi:10.4137/cmo.s531 · Cited by 40
Osteosarcoma of Mandible: A Case Report and Review of Literature
Khorate, M., Goel, S., Singh, M. P., & Ahmed, J. (2010) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000036 · Cited by 40
“The five year survival rate was predicted to be 65.3% (Bielack et al., 2002).”
Influential
Late Relapse in Osteosarcoma
Ferrari, S. M., Briccoli, A., Mercuri, M., Bertoni, F., Cesari, M., Longhi, A., & Bacci, G. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000212944.82361.1d · Cited by 41
“Tibia 58 (24) 10 (42) Humerus 28 (12) 1 (4) Other 18 (7) 2 (8) SAP* Normal 101 (45) 11 (48) 0.”
Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome
Kersting, C., Gebert, C., Agelopoulos, K., Schmidt, H., van Diest, P. J., Juergens, H., Winkelmann, W., Kevric, M., Gosheger, G., Brandt, B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2432 · Cited by 40
Self-citation
Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine: Ifosfamide-Containing Chemotherapy In Osteosarcoma
Anderson, P. M. (2006) · Future Oncology · doi:10.2217/14796694.2.3.333 · Cited by 40
Hsa_circ_0000285 functions as a competitive endogenous RNA to promote osteosarcoma progression by sponging hsa-miRNA-599
Zhang, Z., Pu, F., Wang, B., Wu, Q., Liu, J., & Shao, Z. (2019) · Gene Therapy · doi:10.1038/s41434-019-0112-5 · Cited by 39
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis
Nirala, B. K., Yamamichi, T., & Yustein, J. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411367 · Cited by 42
“Tumor metastasis is the primary challenge for OS therapy [8].”
Background
Phytocompounds and Nanoformulations for Anticancer Therapy: A Review
Bozzuto, G., Calcabrini, A., Colone, M., Condello, M., Dupuis, M. L., Pellegrini, E., & Stringaro, A. (2024) · Molecules · doi:10.3390/molecules29163784 · Cited by 42
Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin
PosthumaDeBoer, J., van Egmond, P. W., Helder, M. N., de Menezes, R. X., Cleton-Jansen, A., Beliën, J. A. M., Verheul, H. M. W., van Royen, B. J., Kaspers, G. J. L., & van Beusechem, V. W. (2012) · Oncotarget · doi:10.18632/oncotarget.600 · Cited by 39
“com/oncotarget disease, 5-year survival rates are reduced to only 20% [1-4].”
Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment
Perut, F., Carta, F., Bonuccelli, G., Grisendi, G., Pompo, G. D., Avnet, S., Sbrana, F. V., Hosogi, S., Dominici, M., Kusuzaki, K., et al. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1086339 · Cited by 39
“Today, the gold standard for OS therapy consists of a combination of multi-agent neoadjuvant chemotherapy, followed by radical surgery and adjuvant chemotherapy [43,44].”
Background
Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma
Marais, L. C., Bertie, J., Rodseth, R. N., Sartorius, B. K. D., & Ferreira, N. (2015) · Journal of bone oncology · doi:10.1016/j.jbo.2015.09.002 · Cited by 38
Screening of diagnostic markers for osteosarcoma
Wu, D., Chen, K., Bai, Y., Zhu, X., Chen, K., Wang, C., Zhao, Y., & Li, M. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2546 · Cited by 39
“Osteosarcoma is a common clinical malignant bone tumor, representing ~35% of cases and constituting ~0.07% of all the neoplasms (1), and it mainly targets the adolescent age group (2).”
BackgroundInfluential
Prognostic factors of pulmonary metastasectomy for osteosarcomas of the extremities
Chen, F., Miyahara, R., Bando, T., Okubo, K., Watanabe, K., Nakayama, T., Toguchida, J., & Date, H. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.07.032 · Cited by 39
Osteosarcoma of the mobile spine
Zils, K., Bielack, S., Wilhelm, M., Werner, M., Schwarz, R., Windhager, R. H., Hofmann-Wackersreuther, G., Andus, T., Kager, L., Kühne, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt154 · Cited by 40
“With such an aggressive approach, prognosis may become comparable with that of osteosarcoma of the extremities [29].”
BackgroundSelf-citation
Focal adhesion kinase overexpression and its impact on human osteosarcoma
Ren, K., Lu, X., Yao, N., Chen, Y., Yang, A., Chen, H., Zhang, J., Wu, S., Shi, X., Wang, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5044 · Cited by 39
Survival and prognostic factors in Chinese patients with osteosarcoma: 13-year experience in 365 patients treated at a single institution
Wang, W., Yang, J., Wang, Y., Wang, D., Han, G., Jia, J., Xu, M., & Bi, W. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.11.009 · Cited by 39
Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation
Kany, S., Woschek, M., Kneip, N., Sturm, R., Kalbitz, M., Hanschen, M., & Relja, B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4288 · Cited by 39
“Here, predominantly the metaphyses of long bones, especially at the knee joints in distal femur and proximal tibia are affected (4).”
Emerging Roles of Circular RNAs in Osteosarcoma
Wang, C., Ren, M., Zhao, X., Wang, A., & Wang, J. (2018) · Medical Science Monitor · doi:10.12659/msm.912092 · Cited by 39
G721-0282 inhibits cell growth and induces apoptosis in human osteosarcoma through down-regulation of the STAT3 pathway
Park, K., Yun, H., & Hong, J. T. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.37781 · Cited by 39
“Its pathogenesis is not yet fully understood, and there is an urgent need for more effective treatment (1, 3).”
Background
Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma
Hundsdoerfer, P., Albrecht, M. R., Rühl, U., Fengler, R., Kulozik, A. E., & Henze, G. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.006 · Cited by 39
CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients
Baumhoer, D., Elsner, M., Smida, J., Zillmer, S., Rauser, S., Schöne, C., Balluff, B., Bielack, S., Jundt, G., Walch, A. K., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.398 · Cited by 39
“However, although 5-year survival rates of up to 5070% can be achieved using current treatment protocols, a substantial group of patients with metastatic, recurrent and/or refractory disease is still left without effective treatment options [2, 3].”
BackgroundSelf-citation
Long-Term Outcomes following Lower Extremity Sarcoma Resection and Reconstruction with Vascularized Fibula Flaps in Children
Sainsbury, D. C. G., Liu, E. H., Alvarez‐Veronesi, M. C., Ho, E. S., Hopyan, S., Zuker, R. M., & Borschel, G. H. (2014) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000000555 · Cited by 39
“1 (1) Bone graft to fractured allograft 2 (2) Wound débridement and direct closure and hardware removal, insertion of intramedullary nail 3 (3) ORIF of fracture, removal of hardware, femoral lengthening with external fixator for LLD 3 (4) Contralateral distal femoral epiphysiodesis for LLD 4 (5) Hardware removal, revi…”
BackgroundMethodInfluential
Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR
Lin, S., Shao, N.-N., Fan, L., Ma, X., Pu, F., & Shao, Z. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1369-y · Cited by 38
CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin
Han, X., Du, L., Qiao, H., Tu, B., Wang, Y., Qin, A., Dai, K., Fan, Q., & Tang, T. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.002 · Cited by 38
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single‐center experience of 237 patients
Nataraj, V., Batra, A., Rastogi, S., Khan, S. A., Sharma, M. C., Vishnubhatla, S., & Bakhshi, S. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24045 · Cited by 38
Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway
Miao, J., Wang, S., Zhang, M., YU, F.-B., Zhang, L., Yu, Z., & Kuang, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3358 · Cited by 38
“Although a 5-year survival rate of up to 50-70% can be achieved by using current treatment protocols, a substantial group of patients with metastatic, recurrent and/ or refractory disease remains without effective treatment options (2).”
Background
Down-Regulation of miR-3928 Promoted Osteosarcoma Growth
Xu, H., Liu, X., & Zhao, J. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358718 · Cited by 37

Authors: Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., Zoubek, A., Jürgens, H., & Winkler, K.
Affiliations: University of Münster (DE)
Corresponding author: Bielack, Stefan S.
ORCID: Bielack, Stefan S.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 776-790
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.776
OpenAlex: W2148077417
Cited by: 2,393
References: 61
Citations by year: 2026: 85 · 2025: 95 · 2024: 112 · 2023: 162 · 2022: 159 · 2021: 167 · 2020: 166 · 2019: 121 · 2018: 114 · 2017: 106 · 2016: 122 · 2015: 139 · 2014: 124 · 2013: 106 · 2012: 75
FWCI: 34.99
Type: journal article
Language: en
Update notices: new_edition (2023-09-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade osteosarcoma, prognostic factors, neoadjuvant chemotherapy, limb-sparing surgery, tumor location, tumor size, chemotherapy response, surgical remission, event-free survival, overall survival, histological response, patient age, sex differences
MeSH terms: Adolescent, Adult, Aged, Bone Neoplasms, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Osteosarcoma, Survival Rate, Multivariate Analysis, Chemotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks